Camber Pharmaceuticals on Thursday announced the launch of pantoprazole sodium delayed-release tablets USP, the generic version of Pfizer's Protonix. The drug is used to treat gastro esophageal reflux disease and damage to the esophagus.
With specialty and biotech drugs claiming an ever-greater share of the pharmaceutical market and spawning a backlash from payers and patients over their high price tags, pharmacy operators are smack in the middle of a growing tug of war between the drug industry, the public and private health plans struggling to keep up with the new drug-cost paradigm.
Teva Pharmaceutical on Tuesday announced the U.S. Supreme Court’s decision in Teva Pharmaceuticals USA vs. Sandoz et al. that reversed the Federal Circuit Court’s judgment of invalidity of Teva’s ‘808 patent for Copaxone (glatiramer acetate injection) 20 mg/mL.
Spurred by market opportunities, short-term market exclusivity for some newly launched single-source generics and rising costs for manufacturing, quality control and raw materials, me-too drug manufacturers have escalated a series of price hikes, some of them significant.
Prasco Labs., Takeda Pharmacuetical Company Limited and Takeda's wholly owned subsidiary Takeda Pharmaceuticals U.S.A. on Tuesday announced that Prasco and TPUSA entered into a distribution and supply agreement for the rights to distribute colchicine tablets, USP, the authorized generic of Colcrys tablets.